We also assessed the stability of the analyte in both plasma and CSF under different storage conditions and validated it on a clinical population in a multicenter, double-blind, placebo-controlled, phase II study performed to assess the role of ambroxol as a potential disease-modifying therapy for GBA1-PD [22]. This evidence concerns the gene GBA1 and Parkinson disease.